Medivir

A research based specialty pharmaceutical company focused on infectious diseases

Carnegie Nordic Healthcare Seminar, March 21-22, 2012

Maris Hartmanis, President & CEO

Medivir today

Strong position in HCV drug development – partnered and internal programs

- The front runner, TMC435, considered "best in class PI" hepatitis C drug
- TMC 435: Global phase III trials fully recruited in G1 patients. Expected regulatory filing in first half of 2013
- Interferon-free combination trials - next major development step



Strong pipeline in R&D

- Strong pipeline of innovative infectious disease drugs
- World class expertise in polymerase and protease drug targets

BioPhausia® – a Medivir company

Integrated company - commercial presence and platform in the Nordics

- Strong brand names, annual sales ~500 MSEK with an EBITDA of ~100 MSEK
- Commercial platform for TMC435 launch in the Nordics

European OTC launch by GSK initiated

- Cold sore drug with an unique, differentiated profile and blue-chip marketing partners. First in-house developed product on the market.

Medivir

Financial performance 2011, segment level

Net sales split (SEK m)	2011 Oct-Dec	2010 Oct-Dec	2011 Jan-Dec	2010 Jan-Dec
Outlicensing and partnership agreements				
One-off payments	0.0	-	401.2	47.1
Pharmaceutical sales	47.5	-	111.2	0.1
Parallel imports	84.7	-	185.9	-
Other services	-0.4	1.3	0.3	7.7
Total	**131.8**	**1.3**	**698.6**	**54.9**

Pharmaceuticals segment (SEK m)	2011 Oct-Dec	2010 Oct-Dec	2011 Jan-Dec	2010 Jan-Dec
Net sales	47.1	1.3	512.7	54.9
EBITDA	-36.3	-55.3	137.6	-128.8
EBITDA %	-77.0%	-4253.8%	26.8%	-234.6%

Parallel Import segment (SEK m)	2011 Oct-Dec	2010 Oct-Dec	2011 Jan-Dec	2010 Jan-Dec
Net sales	84.7	-	185.9	-
EBITDA	0.6	-	-2.3	-
EBITDA %	0.7%	-	-1.2%	-

Commercial presence and platform in the Nordics



Strategy

- Addition of new products to the Nordic commercial platform - allows Medivir to approach its goal of becoming profitable
- Fine-tuning of the commercial platform for launch of TMC435 in the Nordic region
- Strengthening Medivir's position within infectious diseases and in addition evaluation of potential future therapeutic areas through innovation based on the advanced protease and polymerase R&D platform

To become a profitable research-based specialty pharmaceutical company with main focus on infectious diseases

Hepatitis C -
A rapidly evolving treatment landscape

Building a leadership position in hepatitis C

Two major HCV programs partnered with Janssen Pharmaceutica

Protease inhibitor – TMC435

- A potent, once-daily, safe and efficacious protease inhibitor with broad genotypic coverage
- Broad global phase III development program in genotype 1 infected patients
- Phase II interferon and ribavirin free combination studies

Polymerase inhibitor – nucleotide NS5B inhibitor

- A next generation, liver targeted nucleotide polymerase inhibitor program as part of the ongoing partnership
- Clinical drug candidate selected
- Approaching clinical development



Medivir

TMC435, triple combination therapy with INF/RBV

- **Best-in-class potential based on Phase II data**
  - A safe and efficacious drug with excellent tolerability
  - Highly potent with advantageous low pill burden, 1 pill once daily

Study	Patient population	SVR24
PILLAR	Treatment naive	**81 - 86%**
DRAGON	Treatment naive (Japan)	**82%**
ASPIRE	Relapsers	**85%**
	Partial responders	**75%**
	Null responders	**51%**

- **Applicable in broad HCV patient populations**
  - G1 population, the most prevalent and difficult-to-treat
    - Treatment naïve and treatment experienced patients
    - Cirrhotic and non-cirrhotic patients

Robust clinical data, with approximately 1800 patients treated today

Medivir

TMC435, broad clinical development program in HCV genotype 1 & 4 infected patients

Phase III

QUEST 1 treatment-naïve patients; n=375

QUEST 2 treatment-naïve patients; n=375

PROMISE (C3007) prior relapsed patients; n=375

Japan phase III program naïve and experienced patients; n=417 (four studies)

C3001 *prior partial and null responders vs. Telepravir; n=744*

C3011 *naïve and experienced patients; n=100 open label in* ***G4*** *patients*

IFN free combinations in Phase II development

TMC435 and GS-7977, a nucleotide NS5B inhibitor.
12 or 24 weeks, +/- ribavirin in prior null responders; n=180

Trial has started

TMC435 and daclatasvir (BMS-790052), an NS5A inhibitor.
12 and 24 weeks, +/- ribavirin in G1 patients

Trial will start Q2, 2012

Regulatory filings in first half of 2013 in US, EU and Japan

Hepatitis C, a rapidly evolving treatment landscape



TMC435 - key characteristics of optimal DAA cornerstone to cure HCV

Medivir

TMC435, the most advanced DAA in clinical development



TMC435 will be a cornerstone in different future treatment regimes

Medivir

TMC 435, summary

- Documented safe and well tolerated, close to 1800 patients have completed TMC435 treatment. Approximately 1000 additional patients are being recruited for upcoming trials in 2012
- Highly efficacious in G1a/G1b patients, both cirrhotic and non-cirrhotic and high response rates as demonstrated in three large phase 2b trials, PILLAR, ASPIRE and DRAGON
- Pan genotypic coverage G1-6, with the exception of G3
- Directly active on its HCV protease target, *i.e.* does not require serial steps for activation in the liver, like for instance nucleotides
- Can restore endogenous interferon signaling, ablated by the action of the HCV protease
- Low dose, one tablet once daily, a solid base for future combination tablets
- Advancing into two, all oral, interferon-free Phase II combination trials

Best-in-class properties in triple combination standard of care treatment

The Medivir Technology Platform and selected pipeline assets

Building a leadership position in hepatitis C

Two major internal HCV programs, both un-partnered

Nucleotide NS5B inhibitor: in preclinical optimization phase

- A new class of structures identified
- Highly potent molecules with characteristics comparable to the most advanced stage clinical nucleotides
- No observed cytotoxicity
- Patent applications filed
- Aiming for Candidate Drug selection in Q4, 2012

NS5A replication complex inhibitor: in preclinical optimization phase

- A next generation NS5A inhibitor with high barrier to resistance in preclinical phase
- Patent applications filed



Cathepsin K inhibitors – osteoarthritis (OA) and osteoporosis

Disease and market

- **Osteoporosis, osteoarthritis and metastatic bone disease**
- Estimated combined global market opportunity in excess of 12 BUSD

Mechanism of action: Cathepsin K inhibition

- Reduced bone resorption and cartilage breakdown
- Maintained bone formation in contrast to other anti-resorptives

Dog OA model - Results

Urinary biomarkers for bone and cartilage resorption reduced by 86% and 80% respectively ($p<0.001$)

Gross scores of bone and cartilage pathology reduced by 13-37 % in OA model in dog ($p <0.05$)

Next step

- MIV-711 in preclinical development, aiming for start of phase I clinical trials in Q2 2012



Preclinical support for beneficial effects of Cathepsin K inhibition in both osteoarthritis and osteoporosis

Cathepsin S inhibitor – neuropathic pain and rheumatoid arthritis

Disease and market

- Approximately 25 million patients worldwide suffer from neuropathic pain
- Estimated global market opportunity for neuropathic pain in excess of 2.3 BUSD, and rheumatoid arthritis is estimated to 7 BUSD

Mechanism of action: Cathepsin S inhibition

- Inhibition of Cathepsin S prevents inflammatory damage to the sensory system in the spinal cord by blocking Fractalkine activation

Cathepsin S inhibitor program

- Potent, selective and orally bioavailable inhibitors developed by Medivir

Next step

- Candidate drug selection potentially in Q4 2012

Principle for neuropathic pain



Important key messages

- Integrated pharmaceutical company - commercial platform in the Nordic region allows us to expand R_x portfolio and move towards becoming a profitable research driven specialty pharmaceutical company
- TMC435, a best in class protease inhibitor is strongly positioned to become the principal cornerstone of future interferon-free therapies
- Our hepatitis C portfolio, including TMC435, gives room for a broad approach in hepatitis C drug development including DAA combinations.
- Strong track record in innovation
- Many external partnerships validating core R&D platform

A solid platform for future growth

Expected key news flow highlights

- ✓ Q4-11 Agreement signed to evaluate TMC435 and daclatasvir (BMS-790052) in DAA combination trials
- ✓ Q1-12 DAA phase II combination study with TMC435 and GS-7977 started
- ✓ Q1-12 OTC launch of Xerclear® (ZoviDuo) in Europe by GSK
- ✓ Q1-12 FY report and update on projects and financials
- ✓ Q1-12 Start of Phase III trials with TMC435 + standard of care in prior null and partial responder patients (C3001) versus Telaprevir. Screening has started.
- ✓ Q1-12 Application to start phase I trials with cathepsin K filed with authorities
- Q2-12 EASL – ASPIRE full SVR24 data
- Q2-12 Start of DAA phase II combination study with TMC435 and daclatasvir
- Q2-12 Goal to start Phase I trials with MIV-711
- Q4-12 Potential CD selection in our internal Nucleotide NS5B inhibitor program
- Q4-12 EoT-data from Cohort 1 with TMC435 and GS7977 DAA phase II study
- Q4-12 Potential CD selection in Cathepsin S (Neuropathic pain) program
- Q4-12 Goal to start phase 1 trials with Medivir/Janssen Nucleotide NS5B inhibitor
- Q4-12 AASLD
- Q4-12 Top line results from phase III trials with TMC435 (Quest 1+2 and Promise)